Earnings Calls

Chubb has now posted four consecutive EPS beats, with this quarter's $6.82 vs $6.61 print extending the streak. The stock has historically traded in a tight band around earnings — typical post-print moves under ±2% — and this week's -1.6% reaction was consistent with that pattern, despite the headline beat. Property-cat heavy quarters have historically produced muted reactions even on EPS beats as the market focuses on combined ratio rather than EPS.

Forward focus is on the disclosed wildfire cat-loss number and what it implies for full-year combined ratio and reinsurance pricing into 2026 renewals. Commercial line rate trends, Asia-Pacific life integration economics, and book value growth are the metrics analysts will reset on. The 23-analyst panel has a buy consensus with a $345 mean PT versus $324.66 current — implying ~6% upside from current levels.

United Airlines has now beaten EPS estimates four straight quarters, but the stock has historically had outsized reactions to revenue and unit-revenue (RASM) commentary rather than EPS itself. This week's -7.1% decline despite a $1.19 vs $1.08 EPS beat is consistent with prior quarters where revenue misses ($14.6B reported vs $17.5B expected — a $2.9B shortfall) drove the price action. Airline stocks have historically traded the demand commentary, not the quarter just reported.

Forward focus centers on whether management reinstates the full-year EPS range it pulled in early April and what the Q2 RASM outlook signals about the summer booking curve. Premium cabin trends, international capacity discipline, and any commentary on corporate-travel demand will drive the next leg of estimates. The 24-analyst panel maintains a buy consensus with a $129.83 mean PT against a $91.90 current price — a ~41% implied upside that reflects compressed multiples on demand uncertainty.

UnitedHealth has now beaten EPS three straight quarters; this print extended the streak with $7.23 vs $6.60 estimated, alongside a revenue beat ($113.2B vs $110.9B). Historically, UNH post-earnings moves are tightly correlated with the medical loss ratio disclosure and any FY EPS update — the stock has averaged ±3% on prior prints. This week's +9.6% move was the largest one-week reaction in eight quarters and reflected the convergence of operational delivery with the recent DOJ-probe narrative shift.

Forward focus is on the medical loss ratio trajectory through the back half of 2026, FY EPS guidance reaffirmation or raise, and any explicit DOJ-probe commentary in the Q&A. Optum Health margins and the Medicare Advantage benefit-design cycle are the operational levers analysts will recalibrate. The 26-analyst panel is buy-rated with a $386.08 mean PT against $354.69 current — a ~9% upside that has compressed as the stock has rallied.

Lam Research has posted four consecutive EPS beats, and this quarter's $1.47 vs $1.36 print extended the run, even as revenue ($5.8B) came in below the $6.7B estimate. The stock has historically had outsized reactions to WFE (wafer fab equipment) outlook commentary rather than the quarter just delivered — moves of ±5% on management's forward CapEx commentary are typical. This week's +0.5% reaction was muted relative to historical sensitivity, indicating the print and outlook were largely in line with expectations.

Forward focus is on the FY2026 WFE spending outlook, the AI/HBM share of equipment demand, and any China-export-control commentary that could clip the addressable market. Gross-margin trajectory after recent cost-out, and the cadence of leading-edge logic spending, are the two numbers analysts will calibrate against. The 31-analyst panel is buy-rated with a $305.97 mean PT against $259.56 current — ~18% implied upside.

Texas Instruments has historically traded the capex commentary and FCF trajectory more than the quarter itself — a multi-year capex cycle has compressed FCF and made management's normalization commentary the dominant signal. This week's $1.71 vs $1.37 EPS beat alongside a revenue miss ($4.8B vs $5.2B) and +15.6% week reaction is the largest one-week move in over a year. The magnitude of the rally on a revenue miss indicates forward commentary — likely around capex normalization and an industrial/auto inventory inflection — was the catalyst.

Forward focus is on capex run-rate guidance (still elevated but expected to peak), free-cash-flow recovery cadence, and end-market commentary on industrial and auto demand. The 32-analyst panel — the most-covered name in the slate — has a buy consensus with a $272.75 mean PT against $269.50 current, suggesting the rally has now closed most of the implied upside and analyst PT revisions will be the next catalyst.

Comcast has posted four consecutive EPS beats — this quarter's $0.79 vs $0.73 extended the run — but the stock has historically traded the broadband net-add number and Peacock economics rather than EPS. The -6.3% week reaction following an initial AH pop (+7.7%) is consistent with prior prints where the headline beat faded as the broadband subscriber detail and the Versant cable spin-off timeline came into focus.

Forward focus is on broadband net-adds (likely negative again), wireless ARPU and subscriber trajectory, the Peacock contribution-margin path, and any commentary on the Versant cable spin-off timeline and NBCU asset realignment. The 22-analyst panel is hold-rated — the only non-buy name in this week's slate — with a $33.07 mean PT against $27.51 current, implying ~20% upside that reflects valuation support more than operational momentum.

Procter & Gamble has now posted four consecutive EPS beats, with this quarter's $1.59 vs $1.56 print extending the run alongside a modest revenue miss ($21.2B vs $21.4B). PG's post-earnings moves have historically been small — averaging ±1.5% — given the defensive nature of the business. This week's +2.6% reaction was modestly above that historical average and consistent with the role PG has played in volatile tapes: a defensive ballast.

Forward focus centers on organic sales growth (volume vs. price mix), any FX-adjusted guidance revision given dollar strength (DXY at 98.48), and the commentary on emerging-market demand. Operating margin trajectory and the pace of price-led growth normalization are the metrics analysts will recalibrate against. The 22-analyst panel is buy-rated with a $164.14 mean PT against $148.41 current — ~11% implied upside.